Features of damage to the gastroduodenal zone in patients receiving program hemodialysis therapy

Purpose of the study: to study the clinical and endoscopic features of gastroduodenal involvement in patients with end-stage chronic kidney disease (CKD C5D) receiving replacement therapy with program hemodialysis. Materials and methods: in the process of clinical study on the basis of the dialysis department of the Kirov Regional Clinical Hospital, three groups of patients with chronic kidney disease receiving renal replacement therapy (RRT) with program hemodialysis (KBPS5D) with different lengths of dialysis therapy were sequentially formed. Based on the patients’ complaints from the gastrointestinal tract, the presence of symptoms of gastric dyspepsia was determined. H. Pylori was also determined and esophagogastroduodenoscopy was performed. Results: depending on the duration of RRT with program hemodialysis, features of the pathology of the upper gastrointestinal tract were identified. When assessing the symptoms of gastric dyspepsia, the most common complaints were: nausea, belching, and a feeling of early satiety. In patients of group I the severity and frequency of dyspeptic symptoms were maximum. In patients of group II, the frequency and severity of dyspeptic syndrome is significantly lower than in group I. But with increasing duration of treatment with program hemodialysis, the frequency of dyspepsia symptoms increased again. Esophagogastroduodenoscopy data showed a high prevalence of chronic gastritis and chronic duodenitis in patients with CKD in all groups. Conclusion: patients with CKD S5 during the introduction into program hemodialysis (during the first month of RRT) have a high frequency and clinically pronounced course of concomitant diseases of the upper gastrointestinal tract that reduce quality of life. The duration of RTA with hemodialysis from 1 to 12 months is associated with a moderate frequency of gastroduodenal lesions. With an increase in the duration of RTA for more than a year, the frequency of gastropathies, including erosive ones, increases again. The data obtained indicate the need to study the effect of gastroduodenal lesions on the quality of life, the prognosis of dialysis patients and the creation of recommendations for the prevention, diagnosis and treatment of diseases of the upper gastrointestinal tract accompanying terminal renal failure.

renal replacement therapy, program hemodialysis, chronic gastritis, gastric ulcer, H. pylori

1. Kamyshova, E.S., Zakharova E. V. KDIGO 2012 Clinical Practice Guidelines for the Diagnosis and Treatment of Chronic Kidney Disease. Nephrology and dialysis. 2017; 19(1): 22-206. (In Russ.)@@ Клинические практические рекомендации KDIGO 2012 по диагностике и лечению хронической болезни почек. Перевод с английского Е. С. Камышовой под редакцией Е. В. Захаровой. Нефрология и диализ. 2017; 19(1): 22-206.

2. Clinical guidelines. Chronic kidney disease (CKD). Nephrology. 2021; 25(5): 10-82. (In Russ.) doi: 10.36485/1561-6274-2021-25-5-10-82.@@ Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021; 25(5): 10-82. doi: 10.36485/1561-6274-2021-25-5-10-82.

3. Locatelli F., Vecchio L. D., Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transplant. 2002;17 Suppl 11:2-7. doi: 10.1093/ndt/17.suppl_11.2.

4. Norris K., Vaughn C. The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. Expert Rev Cardiovasc Ther. 2003 May;1(1):51-63. doi: 10.1586/14779072.1.1.51.

5. Shah J.M., Ramsbotham J., Seib C., Muir R., Bonner A. A scoping review of the role of health literacy in chronic kidney disease self-management. J Ren Care. 2021 Dec;47(4):221-233. doi: 10.1111/jorc.12364.

6. Gulyaev A. N., Shishkin A. N., Ferman R. S. et al. Helicobacter pyloriinfection in end-stage renal disease. Nephrology. 2007; 11(4): 59-63. (In Russ.) doi: 10.24884/1561-6274-2007-11-4-59-63.@@ Гуляев А. Н., Шишкин А. Н., Ферман Р. С. и соавт. Инфекция Helicobacter pylori при терминальной стадии хронической болезни почек. Нефрология. 2007; 11(4): 59-63. doi: 10.24884/1561-6274-2007-11-4-59-63.

7. Ryss E.S., Lukichev B. G., Lutoshkin M. A. et al. Digestive system. In: Ryabov S. I., ed. Treatment of chronic renal failure. SPb, 1997. (In Russ.)@@ Рысс Е. С., Лукичев Б. Г., Лутошкин М. А. и соавт. Пищеварительная система. В: Рябов С. И., ред. Лечение хронической почечной недостаточности. СПб.,1997.

8. Zhang X., Bansal N., Go A. S., Hsu C. Y. Gastrointestinal symptoms, inflammation and hypoalbuminemia in chronic kidney disease patients: a cross-sectional study. BMC Nephrol. 2015 Dec 11;16:211. doi: 10.1186/s12882-015-0209-z.

9. Filatov M.A., Simonova Zh. G. Dyspepsia syndrome in patients with stable angina. Vyatka Medical Bulletin. 2020; 3(67): 45-50. (In Russ.)@@ Филатов М. А., Симонова Ж. Г. Синдром диспепсии у больных стабильной стенокардией. Вятский медицинский вестник. 2020; 3(67): 45-50.

10. Jalilov S.S., ShokirovYu.A. Clinical and bacteriological assessment of the pathology of the esophagogastroduodenal zone in chronic kidney disease. Bullet in of the Pedagogical University. 2015; 2(63): 77-83. (In Russ.)@@ Джалилов С. С., Шокиров Ю. А. Клинико-бактериологическая оценка патологии эзофагогастродуоденальной зоны при хронической болезни почек. Вестник Педагогического университета. 2015; 2(63): 77-83.

11. Maev I.V., Andreev D. N. [Helicobacter pylori infection and associated diseases]. Moscow. Remedium, 2018. (In Russ.)@@ Маев И. В., Андреев Д. Н. Инфекция Helicobacter pylori и ассоциированные заболевания. М.: Ремедиум, 2018.

12. Fischbach W., Malfertheiner P. Helicobacter pylori Infection. Dtsch Arztebl Int. 2018 Jun 22;115(25):429-436. doi: 10.3238/arztebl.2018.0429.

13. Morgan D.R., Crowe S. E. Helicobacter pylori infection. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management/edited by M Feldman, LS Friedman, LJBrandt, 2015.

14. Mehrotra R., Davison S. N., Farrington K., Flythe J. E., Foo M., Madero M., Morton R. L., Tsukamoto Y., Unruh M. L., Cheung M., Jadoul M., Winkelmayer W. C., Brown E. A.; Conference Participants. Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 Sep; 104(3): 441-454. doi: 10.1016/j.kint.2023.05.019.

15. Tokushima H. [Role of Helicobacter pylori in gastro-duodenal mucosal lesions in patients with end-stage renal disease under dialysis treatment]. Nihon Jinzo Gakkai Shi. 1995 Sep;37(9):503-10. Japanese. PMID: 7474517.

16. Jaspersen D., Fassbinder W., Heinkele P., Kronsbein H., Schorr W., Raschka C., Brennenstuhl M. Significantly lower prevalence of Helicobacter pylori in uremic patients than in patients with normal renal function. J Gastroenterol. 1995 Oct;30(5):585-8. doi: 10.1007/BF02367783.

17. Cano A.E., Neil A. K., Kang J. Y. et al. Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis. Am J Gastroenterol. 2007 Sep;102(9):1990-7. doi: 10.1111/j.1572-0241.2007.01321.x.

18. Pecoits-Filho R., Barany P., Lindholm B. et al.Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002; 17(9): 1684-8. doi: 10.1093/ndt/17.9.1684.

19. Yong K., Ooi E. M., Dogra G. et al. Elevated interleukin-12 and interleukin-18 in chronic kidney disease are not associated with arterial stiffness. Cytokine. 2013; 64(1): 39-42. doi: 10.1016/j. cyto.2013.05.023.

20. Litun A.V., Simonova Zh.G., Kolmakova E. V. Sodium and ultrafiltration profiling in patients on program hemodialysis: Focus on quality of life. Nephrology and dialysis. 2022; 24(3): 473-479. (In Russ.) doi: 10.28996/2618-9801-2022-3-473-47.@@ Литун А. В., Симонова Ж. Г., Колмакова Е. В. Профилирование натрия и ультрафильтрации у больных на программном гемодиализе: Фокус на качество жизни. Нефрология и диализ. 2022; 24(3): 473-479. doi: 10.28996/2618-9801-2022-3-473-47.